Pyrls

Updated COPD Pharmacotherapy Review and Chart 📊 Available in the Pyrls website or app 🔮

The FDA just approved the first true generic Flovent HFA inhaler, potentially reshaping access and pricing for millions of asthma patients. Read more: rxradio.fm/drug-pricing-a…

Zepbound (tirzepatide) Now Available in Multi-Dose KwikPen

FDA Approves BYSANTI (milsaperidone) for the Treatment of Schizophrenia and Bipolar I Disorder

FDA Approves ADQUEY (difamilast) Topical Ointment for Mild-to-Moderate Atopic Dermatitis

The Uniform MPJE launches in 2026, and it's designed to streamline multi-state licensing and improve portability for pharmacists. Big changes ahead!  Here's what you need to know ⬇️ rxradio.fm/education-and-…

RYBELSUS R2 Tablets (semaglutide) Change Brand Name to OZEMPIC

2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke

FDA Approves NEXPLANON (etonogestrel implant) for Pregnancy Prevention for up to 5 Years

Updated Diabetes Pharmacotherapy Review, Charts, and More 📊 Available in the Pyrls website or app 🔮

FDA Requests Removal of Suicidal Behavior & Ideation Warning from GLP-1 RA Labeling

FDA Approves WEGOVY (semaglutide) Oral Tablet for CV Risk Reduction and Weight Loss

FDA Approves EXDENSUR (depemokimab-ulaa), New Biologic for Severe Asthma

We're excited to announce that @richard_waithe is taking on an even larger role at Pyrls in leading all enterprise growth and operations. Richard brings proven expertise in widening the footprint of digital health solutions for pharmacies. As President of VUCA Health, he scaled the country's largest medication video library and led the company's expansion as the first paperless patient education platform across all 50 states, securing partnerships with major pharmacy system providers before its acquisition. After years as a Pyrls advisor, Richard is stepping into an expanded role to drive our next phase of growth. With 100,000+ clinicians already relying on Pyrls and recent integrations with platforms like EQUIPP Copilot, we're scaling our go-to-market motion and expanding our enterprise partnerships. With Richard's operational leadership, we're positioned to accelerate our growth and expand our impact as we reimagine how clinicians access drug information!

ANDEXXA (andexanet alfa) Withdrawn from the Market

We’re excited to partner with @PharmacyQuality (PQS) by Innovaccer to bring trusted drug info into pharmacists’ workflows. With Pyrls embedded in EQUIPP Copilot™, pharmacists can access clinical insights seamlessly, without toggling screens. Learn more: innovaccer.com/resources/news…

FDA Approves LEROCHOL (lerodalcibep-liga) for LDL-C Reduction and CARDAMYST (etripamil) for Paroxysmal Supraventricular Tachycardia

FDA approves TWO oral therapies for gonorrhea: NUZOLVENCE (zoliflodacin) and BLUJEPA (gepotidacin)

2026 Standards of Care in Diabetes Published

Beta-Lactam Cross-Reactivity Chart 📊 Available on the Pyrls website or app 🔮